Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kirin Pharma Exec Tamao Watanabe On U.S. Biotech-Japan Pharma Collaborations: An Interview with PharmAsia News (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

Tokyo-based Kirin Pharma, which plans to merge with Kyowa Hakko Oct. 1, has done some 35 partnerships since parent company Kirin Brewery entered the pharmaceutical business in 1982. Tamao Watanabe, Kirin Pharma's senior manager of business development for the licensing section in the business development department, recently sat down with PharmAsia News' Tokyo bureau to talk about its partnership with North Carolina-based biotech venture Argos Therapeutics and how to make Japan-Western biotech partnerships work.

You may also be interested in...



Top Japanese Food Maker Ajinomoto To Form Independent Pharma Company

TOKYO - Japan's top food maker Ajinomoto is flexing its muscle to expand its pharmaceutical business by consolidating its two existing companies next April. It would offer more drugs based on its core business of amino acids while allying with or possibly acquiring Japanese and foreign drug makers, an official of the company's pharmaceutical division told PharmAsia News.

Top Japanese Food Maker Ajinomoto To Form Independent Pharma Company

TOKYO - Japan's top food maker Ajinomoto is flexing its muscle to expand its pharmaceutical business by consolidating its two existing companies next April. It would offer more drugs based on its core business of amino acids while allying with or possibly acquiring Japanese and foreign drug makers, an official of the company's pharmaceutical division told PharmAsia News.

Kyowa Hakko Kirin Pledges To Become Japan’s Top Biotech-based Pharma – Bio Japan

YOKOHAMA, Japan - Yuzuru Matsuda, president and CEO of Kyowa Hakko Kirin Co., said his company aimed to become "the top-class global biotechnology-based pharma that does research and development in the area of life sciences out of Japan, continuously making innovative contributions with antibody drugs." Matsuda spoke to an audience at Bio Japan in Yokohama Oct. 17

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069310

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel